Loading clinical trials...
Loading clinical trials...
* This is a prospective, single-center, non-randomized, non-controlled study. * The estrogen receptor (ER), progesterone receptor (PgR), HER2 status and Ki67 index of CNB specimen are critical biomark...
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Peking University
NCT05412225 · Breast Cancer, Invasive Breast Cancer
NCT04368702 · Gastric Cancer, Invasive Breast Cancer, and more
NCT07260188 · Invasive Breast Cancer
NCT04553770 · Early-stage Breast Cancer, Hormone Receptor Positive Breast Carcinoma, and more
NCT03503799 · Primary Invasive Breast Cancer, Estrogen Receptor Positive Tumor, and more
Peking University Cancer Hospital
Beijing, Beijing Municipality
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions